<DOC>
	<DOCNO>NCT02255305</DOCNO>
	<brief_summary>The purpose study determine safety efficacy Fecal Microbiota Transplant ( FMT ) treatment recurrence Clostridium difficile infection ( CDI ) compare standard antibiotic therapy . Patients test positive CDI within 90 day admission relapse CDI approach participate open-label , randomize control trial . Patients either randomized intervention group ( receive FMT via retention enema ) control group ( receive antimicrobial target CDI ) .</brief_summary>
	<brief_title>FMT Versus Antimicrobials Initial Treatment Recurrent CDI</brief_title>
	<detailed_description>This trial open-label , randomize , control trial evaluate safety efficacy fecal microbiota transplantation ( FMT ) treatment recurrence Clostridium difficile infection ( CDI ) compare standard antibiotic therapy . Clostridium difficile infection ( CDI ) increase incidence severity last decade associate poor outcome include increased morbidity , mortality , healthcare cost ( 1-8 ) . Relapse occur 15-35 % patient first episode CDI 45-65 % patient one relapse experience subsequent relapse ( 9 , 10 ) . Dysbiosis - decreased diversity fecal microbiome - think contribute high rate relapse ( 11 ) . FMT quickly successfully restore normal intestinal microorganism diseased patient via infusion liquid stool preparation healthy donor . FMT result disease resolution ~90 % case report systematic review meta-analyses without significant adverse event note ( 12 , 13 ) . All hospitalized patient NorthShore system &gt; 18 year age diagnose active CDI , define &gt; 3 diarrheal stool per day positive C. difficile PCR assay , evaluate inclusion study . Hospitalized patient present first great relapse CDI occur 15 90 day index episode CDI eligible enrollment . Exclusion criterion include pregnancy , neutropenia ( absolute neutrophil count &lt; 1000/Î¼l ) , contraindication retention enema , food allergy control donor diet . Eligible patient undergo write informed consent follow randomization intervention control group . Patients randomized intervention group antimicrobial target C. difficile discontinue least 6 hour prior undergo FMT via retention enema . A second FMT via retention enema administer 24 hour diarrhea persists . Patients randomize control group treat antimicrobial target C. difficile accord Society Healthcare Epidemiology America Clinical Practice Guidelines CDI ( 18 ) . FMT offer control group 90 day experience relapse CDI . Two healthy `` universal '' donor previously donate fecal material FMT express willingness participate study . Donors complete American Association Blood Banks donor questionnaire exposure infectious agent well undergo serologic stool test communicable disease pathogenic bacteria/viruses previously describe ( 17 ) .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<criteria>Diagnosis active C. difficile infection , define &gt; 3 diarrheal stool per day positive C. difficile PCR assay Hospitalized patient present first relapse CDI occur 15 90 day index episode CDI Pregnancy Neutropenia ( absolute neutrophil count &lt; 1000/microliters ) Contraindication retention enema Food allergy control donor diet</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>CDI</keyword>
	<keyword>C difficile</keyword>
	<keyword>C diff</keyword>
	<keyword>Clostridium difficile</keyword>
</DOC>